TY - JOUR
T1 - AllergoOncology
T2 - Microbiota in allergy and cancer—A European Academy for Allergy and Clinical Immunology position paper
AU - Untersmayr, Eva
AU - Bax, Heather J.
AU - Bergmann, Christoph
AU - Bianchini, Rodolfo
AU - Cozen, Wendy
AU - Gould, Hannah J.
AU - Hartmann, Karin
AU - Josephs, Debra H.
AU - Levi-Schaffer, Francesca
AU - Penichet, Manuel L.
AU - O'Mahony, Liam
AU - Poli, Aurelie
AU - Redegeld, Frank A.
AU - Roth-Walter, Franziska
AU - Turner, Michelle C.
AU - Vangelista, Luca
AU - Karagiannis, Sophia N.
AU - Jensen-Jarolim, Erika
N1 - Funding Information:
The AllergoOncology Task Force was financed by the European Academy for Allergy and Clinical Immunology (EAACI). The authors would like to thank EAACI for their financial support in the development of this Task Force position paper. The authors acknowledge support by the Austrian Science Fund FWF grants P23398‐B11, F4606‐B28 (JJE), KLI284 (UE); by the Israel Cancer Association #20161131, the Israel Science Foundation #213/05 the Aimwell Charitable Trust, the Emalie Gutterman Memorial Endowed Fund, the Israel Science Foundation “Center of Excellence /MOKED” and the Israel Ministry of Science, Technology and Space “Personalized Medicine” (LSF); by the National Institutes of Health (NIH) grants R01CA196266, R01CA196266‐ 01A1:S1, and R01 CA181115 (PM); by NIH/NCI grant R03CA173842 and American Society of Hematology Bridge Grant (CW); German Research Council (DFG; HA 2393/6‐1 and Excellence Cluster “Inflammation at Interfaces”) (HK); by IGEM Therapeutics Ltd (BHJ; KSN); by Cancer Research UK (C30122/A11527; C30122/A15774) (KSN, BHJ); The Academy of Medical Sciences (JDH, KSN); the Medical Research Council (MR/L023091/1); Breast Cancer Now—working in partnership with Walk the Walk (KSN); and CR UK/NIHR in England/DoH for Scotland, Wales, and Northern Ireland Experimental Cancer Medicine Centre (C10355/A15587) (KSN); The research was supported by the National Institute for Health Research (NIHR) Biomedical Research Centre based at Guy's and St Thomas’ NHS Foundation Trust and King's College London (IS‐BRC‐1215‐20006) (KSN). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the UK Department of Health; TMC was supported by the Departament de Salut, Generalitat de Catalunya (SLT002/16/00232). ISGlobal is a member of the CERCA Programme, Generalitat de Catalunya. The authors thank BCAM van Esch for her contribution to the section “Nondigestible Oligosaccharides” and to Table 4.
Funding Information:
NIHR National Institute for Health Research, Grant/Award Number: IS-BRC-1215-20006; European Academy of Allergy ande Clinical immunology; Foundation for the National Institutes of Health, Grant/Award Number: R01 CA181115, R01CA196266, R01CA196266-01A1:S1, R03CA173842; Deutsche Forschungsgemeinschaft, Grant/ Award Number: HA 2393/6-1; Aimwell Charitable Trust and Emailie Gutterman Memorial Endowed Fund; Departament de Salut, Generalitat de Catalunya, Grant/ Award Number: SLT002/16/00232; IGEM Therapeutics Ltd; Austrian Science Fund, Grant/Award Number: F4606-B28, KLI284, P23398-B11; The Academy of Medical Sciences; Cancer Research UK, Grant/Award Number: C30122/A11527, C30122/ A15774; Medical Research Council, Grant/ Award Number: MR/L023091/1; Israel Science Foundation, Grant/Award Number: #213/05; Israel Cancer Association, Grant/ Award Number: #20161131; American Society of Hematology; Breast Cancer Now, Grant/Award Number: C10355/A15587; Stop Cancer-USC Norris Comprehensive Cancer Center; Israel Science Foundation “Center of Excellence /MOKED”; Israel Ministry of Science, Technology and Space “Personalized Medicine”; EUE, FRW and EJJ are experts of the Austrian Microbiome initiative amici.
Funding Information:
The AllergoOncology Task Force was financed by the European Academy for Allergy and Clinical Immunology (EAACI). The authors would like to thank EAACI for their financial support in the development of this Task Force position paper. The authors acknowledge support by the Austrian Science Fund FWF grants P23398-B11, F4606-B28 (JJE), KLI284 (UE); by the Israel Cancer Association #20161131, the Israel Science Foundation #213/05 the Aimwell Charitable Trust, the Emalie Gutterman Memorial Endowed Fund, the Israel Science Foundation ?Center of Excellence /MOKED? and the Israel Ministry of Science, Technology and Space ?Personalized Medicine? (LSF); by the National Institutes of Health (NIH) grants R01CA196266, R01CA196266-01A1:S1, and R01 CA181115 (PM); by NIH/NCI grant R03CA173842 and American Society of Hematology Bridge Grant (CW); German Research Council (DFG; HA 2393/6-1 and Excellence Cluster ?Inflammation at Interfaces?) (HK); by IGEM Therapeutics Ltd (BHJ; KSN); by Cancer Research UK (C30122/A11527; C30122/A15774) (KSN, BHJ); The Academy of Medical Sciences (JDH, KSN); the Medical Research Council (MR/L023091/1); Breast Cancer Now?working in partnership with Walk the Walk (KSN); and CR UK/NIHR in England/DoH for Scotland, Wales, and Northern Ireland Experimental Cancer Medicine Centre (C10355/A15587) (KSN); The research was supported by the National Institute for Health Research (NIHR) Biomedical Research Centre based at Guy's and St Thomas? NHS Foundation Trust and King's College London (IS-BRC-1215-20006) (KSN). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the UK Department of Health; TMC was supported by the Departament de Salut, Generalitat de Catalunya (SLT002/16/00232). ISGlobal is a member of the CERCA Programme, Generalitat de Catalunya. The authors thank BCAM van Esch for her contribution to the section ?Nondigestible Oligosaccharides? and to Table.
Publisher Copyright:
© 2019 The Authors. Allergy Published by John Wiley & Sons Ltd.
PY - 2019/6
Y1 - 2019/6
N2 - The microbiota can play important roles in the development of human immunity and the establishment of immune homeostasis. Lifestyle factors including diet, hygiene, and exposure to viruses or bacteria, and medical interventions with antibiotics or anti-ulcer medications, regulate phylogenetic variability and the quality of cross talk between innate and adaptive immune cells via mucosal and skin epithelia. More recently, microbiota and their composition have been linked to protective effects for health. Imbalance, however, has been linked to immune-related diseases such as allergy and cancer, characterized by impaired, or exaggerated immune tolerance, respectively. In this AllergoOncology position paper, we focus on the increasing evidence defining the microbiota composition as a key determinant of immunity and immune tolerance, linked to the risk for the development of allergic and malignant diseases. We discuss novel insights into the role of microbiota in disease and patient responses to treatments in cancer and in allergy. These may highlight opportunities to improve patient outcomes with medical interventions supported through a restored microbiome.
AB - The microbiota can play important roles in the development of human immunity and the establishment of immune homeostasis. Lifestyle factors including diet, hygiene, and exposure to viruses or bacteria, and medical interventions with antibiotics or anti-ulcer medications, regulate phylogenetic variability and the quality of cross talk between innate and adaptive immune cells via mucosal and skin epithelia. More recently, microbiota and their composition have been linked to protective effects for health. Imbalance, however, has been linked to immune-related diseases such as allergy and cancer, characterized by impaired, or exaggerated immune tolerance, respectively. In this AllergoOncology position paper, we focus on the increasing evidence defining the microbiota composition as a key determinant of immunity and immune tolerance, linked to the risk for the development of allergic and malignant diseases. We discuss novel insights into the role of microbiota in disease and patient responses to treatments in cancer and in allergy. These may highlight opportunities to improve patient outcomes with medical interventions supported through a restored microbiome.
KW - allergy
KW - cancer
KW - hygiene hypothesis
KW - microbiota
KW - oncoimmunology
UR - http://www.scopus.com/inward/record.url?scp=85062791620&partnerID=8YFLogxK
U2 - 10.1111/all.13718
DO - 10.1111/all.13718
M3 - Article
C2 - 30636005
AN - SCOPUS:85062791620
SN - 0105-4538
VL - 74
SP - 1037
EP - 1051
JO - Allergy: European Journal of Allergy and Clinical Immunology
JF - Allergy: European Journal of Allergy and Clinical Immunology
IS - 6
ER -